The Biden administration today released findings from 100-day supply chain assessments, determining the need to boost pharmaceutical manufacturing.
According to a fact sheet, the administration plans to take immediate action to “address vulnerabilities and strengthen resilience” with its effort to take on near-term supply chain disruptions for four products: semiconductor manufacturing and advanced packaging; large capacity batteries, like those for electric vehicles; critical minerals and materials; and pharmaceuticals and active pharmaceutical ingredients (APIs).
Get the full story at our sister site, Pharmaceutical Processing World.